Quince Therapeutics (NASDAQ:QNCX) and Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis

Quince Therapeutics (NASDAQ:QNCX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Quince Therapeutics and Autolus Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($0.76)	-0.86
Autolus Therapeutics	$1.70 million	604.07	-$208.38 million	($1.20)	-3.22

Quince Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Quince Therapeutics and Autolus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	0	0	N/A
Autolus Therapeutics	0	1	4	0	2.80

Autolus Therapeutics has a consensus target price of $8.70, indicating a potential upside of 125.39%. Given Autolus Therapeutics’ higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Quince Therapeutics.

Profitability

This table compares Quince Therapeutics and Autolus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-36.72%	-24.12%
Autolus Therapeutics	N/A	-80.21%	-41.47%

Volatility and Risk

Quince Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.

Insider and Institutional Ownership

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Autolus Therapeutics beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.